GH Research Plc (GHRS)
27.57
+0.21
(+0.77%)
USD |
NASDAQ |
Sep 02, 13:59
GH Research Research and Development Expense (TTM) : 46.71M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 46.71M |
| March 31, 2026 | 43.26M |
| December 31, 2025 | 38.73M |
| September 30, 2025 | 35.56M |
| June 30, 2025 | 33.39M |
| March 31, 2025 | 34.19M |
| December 31, 2024 | 35.00M |
| September 30, 2024 | 35.04M |
| June 30, 2024 | 33.73M |
| March 31, 2024 | 31.14M |
| Date | Value |
|---|---|
| December 31, 2023 | 29.79M |
| September 30, 2023 | 28.44M |
| June 30, 2023 | 25.97M |
| March 31, 2023 | 23.05M |
| December 31, 2022 | 20.47M |
| September 30, 2022 | 16.92M |
| June 30, 2022 | 14.86M |
| March 31, 2022 | 12.57M |
| December 31, 2021 | 8.548M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Atai Beckley, Inc. | 79.04M |
| Avadel Pharmaceuticals Plc | 39.89M |
| Jazz Pharmaceuticals Plc | 815.61M |
| Eli Lilly & Co. | 14.60B |
| Perrigo Co. Plc | 95.00M |